The ratio of human glandular kallikrein (hK2) to free PSA improves the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels

被引：0
|
作者：
Magklara, A
Scorilas, A
Catalona, WJ
Diamandis, EP
机构：
[1] Washington Univ, Sch Med, Dept Surg, Div Urol Surg, St Louis, MO 63110 USA
[2] Univ Toronto, Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada
来源：
CLINICAL CANCER RESEARCH | 1999年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
483
引用
收藏
页码：3826S / 3827S
页数：2
相关论文
共 50 条
  • [1] The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA
    Magklara, A
    Scorilas, A
    Catalona, WJ
    Diamandis, EP
    CLINICAL CHEMISTRY, 1999, 45 (11) : 1960 - 1966
  • [2] In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/ml
    Kwiatkowski, MK
    Recker, F
    Piironen, T
    Pettersson, K
    Otto, T
    Wernli, M
    Tscholl, R
    UROLOGY, 1998, 52 (03) : 360 - 365
  • [3] Percent human glandular kallikrein 2 (HK2) to free PSA in serum in the detection of prostate cancer and discrimination of tumor grade
    Becker, C
    Fernlund, P
    Lilja, H
    Hugosson, J
    Piironen, T
    Pettersson, K
    JOURNAL OF UROLOGY, 1998, 159 (05): : 178 - 178
  • [4] Free and total human glandular kallikrein 2 (hk2) in prostate cancer patients
    Väisänen, V
    Alanen, K
    Nurmi, M
    Pettersson, K
    CLINICA CHIMICA ACTA, 2005, 355 : S432 - S433
  • [5] Ratio of free-PSA/total-PSA: An indicator for differentiation between patients with prostate cancer and benign prostatic hyperplasia
    Lein, M
    Stephan, C
    Jung, K
    Koenig, F
    Schnorr, D
    Loening, SA
    AKTUELLE UROLOGIE, 1997, 28 (06) : 323 - 328
  • [6] Serum human glandular kallikrein (hK2) and insulin-like growth factor I (IGF-I) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination WithTotal and %free PSA
    Scorilas, A
    Plebani, M
    Mazza, S
    Brasso, D
    Soosaipillai, AR
    Katsaros, N
    Pagano, F
    Diamandis, EP
    PROSTATE, 2003, 54 (03): : 220 - 229
  • [7] Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung, K
    Elgeti, U
    Lein, M
    Brux, B
    Sinha, P
    Rudolph, B
    Hauptmann, S
    Schnorr, D
    Loening, SA
    CLINICAL CHEMISTRY, 2000, 46 (01) : 55 - 62
  • [8] Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer
    Froehner, M
    Hakenberg, OW
    Koch, R
    Schmidt, U
    Meye, A
    Wirth, MP
    UROLOGIA INTERNATIONALIS, 2006, 76 (01) : 27 - 30
  • [9] Improved discrimination of prostate cancer and benign prostatic hyperplasia by means of the quotient of free and total PSA
    Weckermann D.
    Maassen C.
    Wawroschek F.
    Harzmann R.
    International Urology and Nephrology, 1999, 31 (3) : 351 - 359
  • [10] Use of the Tandem(R) PSA ratio (free/total PSA) in distinguishing between prostate cancer (PCA) and benign prostatic hyperplasia (BPH).
    Southwick, PC
    Catalona, WJ
    Partin, AW
    Ratliff, TL
    Chan, DW
    Walsh, PC
    Subong, ENP
    Kelley, CA
    Gasior, GH
    CLINICAL CHEMISTRY, 1996, 42 (06) : 667 - 667
12345